Perinatal safety of topical corticosteroids for pregnant women

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2008, Pages

  Chi, Ching Chi ^a,e   Lee, Chia Wen ^b   Wojnarowska, Fenella ^c   Kirtschig, Gudula ^d  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c CHURCHILL HOSPITAL   (United Kingdom)

^d VU UNIVERSITY AMSTERDAM   (Netherlands)

^e CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE; BETAMETHASONE DIPROPIONATE; BUDESONIDE; CORTICOSTEROID; DEXAMETHASONE; DIFLORASONE DIACETATE; FLUTICASONE; HYDROCORTISONE; METHYLPREDNISOLONE; PREDNISOLONE;

COHORT ANALYSIS; DATA ANALYSIS; DATA SYNTHESIS; DRUG DOSE INCREASE; DRUG SAFETY; HUMAN; INFORMATION PROCESSING; NONHUMAN; NONRESPONSE BIAS; OUTCOME ASSESSMENT; PERINATAL CARE; PREGNANT WOMAN; REVIEW; RISK ASSESSMENT; SENSITIVITY ANALYSIS;

EID: 55049136795     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007346     Document Type: Review

References (45)

1. Ambros-Rudolph 2006 Ambros-Rudolph CM. Dermatoses of pregnancy. Journal der Deutschen Dermatologischen Gesellschaft 2006;4(9):748- 61. [: doi:10.1111/j.1610-0387.2006.06008.x]
2. Anderson 1981 Anderson GG, Rotchell Y, Kaiser DG. Placental transfer of methylprednisolone following maternal intravenous administration. Amer-ican Journal of Obstetrics and Gynecology 1981;140(6):699- 701.
3. Ballard 1975 Ballard PL, Granberg P, Ballard RA. Glucocorticoid levels in maternal and cord serum after prenatal betamethasone therapy to prevent respiratory distress syndrome. Journal of Clinical Investigation 1975;56(6):1548-54.
4. Ballard 1977 Ballard PD, Hearney EF, Smith MB. Comparative teratogenicity of selected glucocorticoids applied ocularly inmice. Teratology 1977;16(2):175-80.
5. Baumann 1999 Baumann L, Kerdel F. Topical glucocorticoids. In: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, et al. editor (s). Fitzpatrick's Dermatology in General Medicine. 5th Edition. New York: McGraw-Hill, 1999:2713-7.
6. Beitins 1972 Beitins IZ, Bayard F, Ances IG, Kowarski A, Migeon CJ. The transplacental passage of prednisone and prednisolone in pregnancy near term. The Journal of Pediatrics 1972;81(5):936-45.
7. Berth-Jones 2004 Berth-Jones J. Topical therapy. In: Burns T, Breathnach SM, Cox N, Griffiths C editor(s). Rook's Textbook of Dermatology. 7th Edition. Oxford: Blackwell Publishing, 2004:75.1-52.
8. Carmichael 1999 Carmichael SL, Shaw GM. Maternal corticosteroid use and risk of selected congenital anomalies. American Journal of Medical Genetics 1999;86(3):242-4.
9. Casey 2001 Casey BM, McIntire DD, Leveno KJ. The continuing value of the Apgar score for the assessment of newborn infants. New England Journal of Medicine 2001;344(7):467-71.
10. Cunningham 2005 Cunningham FG, Leveno KJ, Bloom SL, Hauth JC, Gilstrap LC, III, Wenstrom KD. Williams Obstetrics. 22nd Edition. New York: McGraw-Hill, 2005.
11. Czeizel 2005 Czeizel AE. Birth defects are preventable. International Journal of Medical Sciences 2005;2(3):91-2.
12. Gitau 1998 Gitau R, Cameron A, Fisk NM, Glover V. Fetal exposure tomaternal cortisol. Lancet 1998;352(9129):707-8.
13. Gitau 2001 Gitau R, Fisk NM, Teixeira JM, Cameron A, Glover V. Fetal hypothalamic-pituitary-adrenal stress responses to invasive procedures are independent ofmaternal responses. Journal of Clinical Endocrinology and Metabolism 2001;86(1):104-9.
14. GlaxoSmithKline 2002 GlaxoSmithKline. Cutivate cream prescribing information. 2002.
15. Gur 2004 Gur C, Diav-Citrin O, Shechtman S, Arnon J, Ornoy A. Pregnancy outcome after first trimester exposure to corticosteroids: a prospective controlled study. Reproductive Toxicology 2004;18(1):93-101.
16. Hardy 2006 Hardy JR, Leaderer BP, Holford TR, Hall GC, Bracken MB. Safety of medications prescribed before and during early pregnancy in a cohort of 81,975 mothers from the UK General Practice Research Database. Pharmacoepidemiology and Drug Safety 2006;15(8):555-64.
17. Hengge 2006 Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. Journal of the American Academy of Dermatology 2006;54(1):1-18.
18. Ikegami 1997 Ikegami M, Jobe AH, Newnham J, Polk DH, Willet KE, Sly P. Repetitive prenatal glucocorticoids improve lung function and decrease growth in preterm lambs. American Journal of Respiratory and Critical Care Medicine 1997;156(1):178-84.
19. Jessop 2000 Jessop S, Whitelaw D, Jordaan F. Drugs for discoid lupus erythematosus. Cochrane Database of Systematic Reviews 2000, Issue 2. [DOI: DOI: 10.1002/14651858.CD002954.; MEDLINE: Art. No.: CD002954.]
20. Juni 2001 Juni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ 2001;323(7303):42-6.
21. Khumalo 2005 Khumalo N, Kirtschig G, Middleton P, Hollis S, Wojnarowska F, Murrell D. Interventions for bullous pemphigoid. Cochrane Database of Systematic Reviews 2005, Issue 3. [DOI:10.1002/14651858. CD002292.pub2]
22. Loke 2007 Loke YK, Price D, Herxheimer A. Systematic reviews of adverse effects: framework for a structured approach. BMC Medical Research Methodology 2007;7:32.
23. Marsland 2006 Marsland AM, Chalmers RJG, Hollis S, Leonardi-Bee J, Griffiths CEM. Interventions for chronic palmoplantar pustulosis. Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI:10.1002/14651858. CD001433.pub2]
24. Meadows 2001 Meadows M. Pregnancy and the drug dilemma. FDA Consumer 2001;35(3):16-20.
25. Mehta 2006 Mehta DK. British National Formulary. British National Formulary. 2nd Edition. BMJ Publishing Group Ltd and RPS Publishing, 2006: BMJ Publishing Group Ltd and RPS Publishing 2006.
26. Murphy 1974 Murphy BE, Clark SJ, Donald IR, Pinsky M, Vedady D. Conversion of maternal cortisol to cortisone during placental transfer to the human fetus. American Journal of Obstetrics and Gynecology 1974;118(4):538-41.
27. Murphy 2007 Murphy VE, Fittock RJ, Zarzycki PK, Delahunty MM, Smith R, Clifton VL. Metabolism of synthetic steroids by the human placenta. Placenta 2007;28(1):39-46.
28. Nanda 1970 Nanda R, van der Linden FP, Jansen HW. Production of cleft palate with dexamethasone and hypervitaminosis A in rat embryos. Experientia 1970;26(10):1111-2.
29. Narama 1984 Narama I. Reproduction studies of diflorasone diacetate (DDA) (4) Teratogenicity study in rabbits by percutaneous administration. Pharmacometrics 1984;28(2):241-50.
30. Nasjleti 1967 Nasjleti CE, Avery JK, Spencer HH, Walden JM. Tritiated cortisone distribution and induced cleft palate in mice. Journal of Oral Therapeutics and Pharmacology 1967;4(1):71-82.
31. Park-Wyllie 2000 Park-Wyllie L, Mazzotta P, Pastuszak A, Moretti ME, Beique L, Hunnisett L, et al.Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 2000;62(6):385-92.
32. Petersen 1980 Petersen MC, Nation RL, Ashley JJ, McBride WG. The placental transfer of betamethasone. European Journal of Clinical Pharmacology 1980;18(3):245-7.
33. Rodriguez-Pinil 1998 Rodriguez-Pinilla E, Martinez-Frias ML. Corticosteroids during pregnancy and oral clefts: a case-control study. Teratology 1998;58(1):2-5.
34. Schering 2003 Schering. ELOCON cream prescribing information. 2003.
35. Shah 1976 Shah RM, Kilistoff A. Cleft palate induction in hamster fetuses by glucocorticoid hormones and their synthetic analogues. Journal of Embryology and Experimental Morphology 1976;36(1):101-8.
36. Sifton 2002 Sifton DW. Physicians' Desk Reference. 6th Edition. Montvale: Medical Economics Company, 2002.
37. Smith 1988 Smith MA, Thomford PJ, Mattison DR, Slikker W, Jr. Transport and metabolism of dexamethasone in the dually perfused human placenta. Reproductive Toxicology 1988;2(1):37-43.
38. Sun 1998 Sun K, Yang K, Challis JR. Glucocorticoid actions and metabolism in pregnancy: implications for placental function and fetal cardiovascular activity. Placenta 1998;19(5-6):353-60.
39. Taro 1999 Taro Pharmaceuticals. Diflorasone diacetate creamprescribing information. 1999.
40. Turpeinen 1988 Turpeinen M, Mashkilleyson N, Bjorksten F, Salo OP. Percutaneous absorption of hydrocortisone during exacerbation and remission of atopic dermatitis in adults. Acta Dermato-Venereologica 1988;68(4):331-5.
41. Turpeinen 1989 Turpeinen M. Adrenocortical response to adrenocorticotropic hormone in relation to duration of topical therapy and percutaneous absorption of hydrocortisone in children with dermatitis. European Journal of Pediatrics 1989;148(8):729-31.
42. Uno 1994 Uno H, Eisele S, Sakai A, Shelton S, Baker E, DeJesus O, et al.Neurotoxicity of glucocorticoids in the primate brain. Hormones and Behavior 1994;28(4):336-48.
43. Walker 1967 Walker BE. Induction of cleft palate in rabbits by several glucocorticoids. Proceedings of the Society for Experimental Biology and Medicine 1967;125(4):1281-4.
44. Wells 2006 Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al.The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. www.ohri.ca/programs/ clinical_epidemiology/oxford.htm (accessed 23 November 2006).
45. Yamada 1981 Yamada H, Nakano M, Ichihashi T. Fetal concentration after topical application of betamethasone 17,21-dipropionate (S-3440) ointment and teratogenesis in mice and rabbits. Pharmacometrics 1981;21(4):645-55.